-DOCSTART- -X- O
Severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
newly -X- _ O
emerging -X- _ O
infectious -X- _ O
disease. -X- _ O
The -X- _ O
potential -X- _ O
recurrence -X- _ O
of -X- _ O
the -X- _ O
disease -X- _ O
from -X- _ O
animal -X- _ O
reservoirs -X- _ O
highlights -X- _ O
the -X- _ O
significance -X- _ O
of -X- _ O
development -X- _ O
of -X- _ O
safe -X- _ O
and -X- _ O
efficient -X- _ O
vaccines -X- _ O
to -X- _ O
prevent -X- _ O
a -X- _ O
future -X- _ O
SARS -X- _ O
epidemic. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
expressed -X- _ O
the -X- _ O
recombinant -X- _ B-Intervention
receptor-binding -X- _ I-Intervention
domain -X- _ I-Intervention
( -X- _ I-Intervention
rRBD -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ I-Intervention
mammalian -X- _ I-Intervention
( -X- _ I-Intervention
293T -X- _ I-Intervention
) -X- _ I-Intervention
cells -X- _ I-Intervention
, -X- _ I-Intervention
insect -X- _ I-Intervention
( -X- _ I-Intervention
Sf9 -X- _ I-Intervention
) -X- _ I-Intervention
cells -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
E. -X- _ I-Intervention
coli -X- _ I-Intervention
, -X- _ O
respectively -X- _ O
, -X- _ O
and -X- _ O
compared -X- _ O
their -X- _ O
immunogenicity -X- _ O
and -X- _ O
protection -X- _ O
against -X- _ O
SARS-CoV -X- _ B-Patient
infection -X- _ I-Patient
in -X- _ I-Patient
an -X- _ I-Patient
established -X- _ I-Patient
mouse -X- _ I-Patient
model. -X- _ I-Patient
Our -X- _ O
results -X- _ O
show -X- _ O
that -X- _ O
all -X- _ B-Outcome
rRBD -X- _ I-Outcome
proteins -X- _ I-Outcome
expressed -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
above -X- _ I-Outcome
systems -X- _ I-Outcome
maintained -X- _ I-Outcome
intact -X- _ I-Outcome
conformation -X- _ I-Outcome
, -X- _ I-Outcome
being -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
highly -X- _ I-Outcome
potent -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
complete -X- _ I-Outcome
protective -X- _ I-Outcome
immunity -X- _ I-Outcome
against -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
challenge -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
albeit -X- _ I-Outcome
the -X- _ I-Outcome
rRBD -X- _ I-Outcome
expressed -X- _ I-Outcome
in -X- _ I-Outcome
293T -X- _ I-Outcome
cells -X- _ I-Outcome
elicited -X- _ I-Outcome
stronger -X- _ I-Outcome
humoral -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
with -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
neutralizing -X- _ I-Outcome
activity -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
expressed -X- _ I-Outcome
in -X- _ I-Outcome
Sf9 -X- _ I-Outcome
and -X- _ I-Outcome
E. -X- _ I-Outcome
coli -X- _ I-Outcome
cells. -X- _ I-Outcome
These -X- _ I-Outcome
results -X- _ I-Outcome
suggest -X- _ I-Outcome
that -X- _ I-Outcome
all -X- _ I-Outcome
three -X- _ I-Outcome
rRBDs -X- _ I-Outcome
are -X- _ I-Outcome
effective -X- _ I-Outcome
in -X- _ I-Outcome
eliciting -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
and -X- _ I-Outcome
any -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
above -X- _ I-Outcome
expression -X- _ I-Outcome
systems -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
used -X- _ I-Outcome
for -X- _ I-Outcome
production -X- _ I-Outcome
of -X- _ I-Outcome
rRBD-based -X- _ I-Outcome
SARS -X- _ I-Outcome
subunit -X- _ I-Outcome
vaccines. -X- _ I-Outcome
Preference -X- _ O
will -X- _ O
be -X- _ O
given -X- _ O
to -X- _ O
rRBD -X- _ B-Intervention
expressed -X- _ I-Intervention
in -X- _ I-Intervention
mammalian -X- _ I-Intervention
cells -X- _ I-Intervention
for -X- _ O
future -X- _ O
evaluation -X- _ O
of -X- _ O
the -X- _ O
vaccine -X- _ O
efficacy -X- _ O
in -X- _ O
a -X- _ O
non-human -X- _ O
primate -X- _ O
model -X- _ O
of -X- _ O
SARS -X- _ O
because -X- _ O
of -X- _ O
its -X- _ O
ability -X- _ O
to -X- _ O
refold -X- _ O
into -X- _ O
a -X- _ O
native -X- _ O
conformation -X- _ O
more -X- _ O
readily -X- _ O
and -X- _ O
to -X- _ O
induce -X- _ B-Outcome
higher -X- _ I-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
than -X- _ O
those -X- _ O
expressed -X- _ O
in -X- _ O
E. -X- _ O
coli -X- _ O
and -X- _ O
insect -X- _ O
cells -X- _ O
. -X- _ O

